Press release
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
| Press release
Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer
| Press release
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
| Press release
Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
| Press release
Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
| Press release
